Jan 31, 2017 12:01 pm UTC| Business
– First Patient Treated with Non-viral Sleeping Beauty Modified CAR-T Cells Produced in 2 Weeks – Anticipate Phase 1 Clinical Trial Launch in 2017 with Administration of Sleeping Beauty CAR-T Cells Produced within 2 Days–...
Jan 31, 2017 12:01 pm UTC| Business
– First Patient Treated with Non-viral Sleeping Beauty Modified CAR-T Cells Produced in 2 Weeks – Anticipate Phase 1 Clinical Trial Launch in 2017 with Administration of Sleeping Beauty CAR-T Cells Produced within 2 Days–...
Jan 31, 2017 12:01 pm UTC| Business
SANTA MONICA, Calif., Jan. 31, 2017 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders,...
Jan 31, 2017 12:01 pm UTC| Business
SANTA MONICA, Calif., Jan. 31, 2017 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders,...
Jan 31, 2017 12:01 pm UTC| Business
DENVER, Jan. 31, 2017 -- Sundance Energy Australia Limited (ASX:SEA) (NASDAQ:SNDE) (“Sundance” or the “Company”), a U.S. onshore oil and gas exploration and production company focused in the Eagle Ford in South Texas,...
Jan 31, 2017 12:01 pm UTC| Business
DENVER, Jan. 31, 2017 -- Sundance Energy Australia Limited (ASX:SEA) (NASDAQ:SNDE) (“Sundance” or the “Company”), a U.S. onshore oil and gas exploration and production company focused in the Eagle Ford in South Texas,...
Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board
Jan 31, 2017 12:00 pm UTC| Business
WALTHAM, Mass., Jan. 31, 2017 -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer...